A record year of out-licensing pulled the West’s early pipeline sourcing toward Shanghai and Suzhou. The discount that started it is already being competed away. What outlasts it is a two-source model for global pharma innovation.
For most of the past decade, a clinical-stage molecule out of Shanghai or Suzhou could be acquired for roughly the price of a Western Series B. That window is closing, and the manner in which it is closing says more about the next five years of pharma dealmaking than any single transaction does.
Western drugmakers signed roughly $137.7 billion in licensing transactions in 2025, and a disproportionate share of that money went to assets originated in China rather than in Cambridge or South San Francisco [1]. Greater China companies closed 186 cross-border out-licensing deals over the year, nearly triple the 65 they had closed the year before [2]. Early-pipeline sourcing has moved east, and buyers are paying more with each passing quarter to hold their place in line.
The year the checkbooks opened
The marquee deals of 2025 show where the conviction sat. Pfizer paid 3SBio $1.25 billion upfront, took a $100 million equity stake, and layered on as much as $4.8 billion in milestones for global rights outside China to SSGJ-707, a PD-1/VEGF bispecific antibody [4]. GSK committed $500 million upfront to Jiangsu Hengrui Pharmaceuticals for a COPD candidate, HRS-9821, plus options on eleven further programs spanning respiratory, immunology, and oncology, a package that reaches roughly $12 billion in biobucks if the portfolio delivers [5]. In each case, the buyer sourced a clinical-stage asset at a price it could not have matched with a comparable Western molecule.
Below the headlines, the same behavior repeated. Merck spent $588 million to enter the PD-1/VEGF race through LaNova Medicines, then separately paid Hengrui $200 million upfront for a Phase 2 cardiac program [6][7]. Takeda licensed two late-stage Innovent Biologics oncology assets, IBI363 and IBI343, in October for $1.2 billion upfront and as much as $11.4 billion in total consideration [8]. BioNTech went a step further and bought Biotheus outright for $800 million to own its position in the same bispecific class [4]. Read together, the deals look less like opportunism and more like a deliberate reassessment of where usable innovation is now being generated.
2026 has run hotter still
The pace did not ease into the new year. Greater China companies booked a record $60 billion in cross-border out-licensing value in the first quarter of 2026 alone, a 73% jump on the same quarter a year earlier and close to half of the entire 2025 total compressed into three months [16]. The average deal size reached $1.3 billion, up 76% from the 2025 average and roughly six times the 2021 level [15].
The buyer list widened in step. AbbVie opened the year by licensing RemeGen’s antibody-drug conjugate RC148, for advanced solid tumors, in a deal worth up to $5.6 billion [14]. AstraZeneca returned to CSPC for a weight-management portfolio worth up to $18.5 billion, with $1.2 billion paid upfront, its second major pull from the same Shijiazhuang company [14]. Sanofi licensed rovadicitinib from Sino Biopharm’s Chia Tai Tianqing unit in early March for up to $1.53 billion [14]. By late March, Eli Lilly had broadened its Insilico Medicine relationship into a licensing and research pact worth up to $2.75 billion, a wager on AI-generated chemistry [14]. Hengrui handed its cardiomyopathy candidate HRS-1893 to Braveheart Bio, a startup backed by Forbion and OrbiMed, for about $1.1 billion [10]. And in February, Madrigal Pharmaceuticals licensed liver-disease siRNA programs from Suzhou Ribo Life Science for $60 million upfront against a total of up to $4.4 billion [15].
Two features separate this year from last. The assets changing hands are earlier than their price tags imply: close to three-quarters of 2025’s cross-border pacts involved drugs still in preclinical or Phase 1 testing, so buyers are paying for conviction well ahead of mature data [17]. The structures are diversifying too, from straight ex-China licenses toward NewCo vehicles like Braveheart that route Western venture money directly into Chinese assets while the originator keeps its upside. Bank of America’s Asia-Pacific M&A head expects total licensing-out value to double again within two years, the run rate against which the back half of the decade will be measured [15].
What is actually driving it
The easy explanation is that China got cheap and the West went shopping. The real causes run deeper, and they show no sign of reversing on their own.
The first is the patent cliff. GlobalData estimates that US drug sales will fall by $230 billion between 2025 and 2030 as a wave of blockbusters loses exclusivity [9]. No internal R&D engine can refill a hole that size on that timeline, so large pharma is buying optionality wherever it can be had most cheaply per unit of risk-adjusted return. The second is that the Chinese asset class has matured. Chinese innovators now account for close to 90% of global antibody-drug conjugate licensing activity, and they are moving quickly into bispecifics, protein degraders, and cell therapy [10]. Chinese-origin drugs made up 28% of the innovator licensing deals signed by large pharma in 2024, worth $41.5 billion [9]. The third is the arithmetic of speed and cost: Chinese discovery runs 30% to 40% below US and European equivalents, and trials enroll two to three times faster against a large and concentrated patient population [10].
Set that against how the West has historically priced its own science. American and European biotechs still treat their assets as scarcity goods, a habit formed over the two decades when they largely were. Chinese assets, by contrast, have carried upfronts 60% to 70% lower than Western peers, with total deal sizes 40% to 50% smaller [11]. That gap was the whole opportunity, and it is being competed away in plain view. The average upfront on a Western-to-China licensing deal has climbed 230%, from $52 million in 2022 to roughly $172 million so far in 2026 [3]. China represented 21% of global out-licensing value across 2023 and 2024; by the first quarter of 2025, it had reached 32% [2].
Geopolitics shapes the plumbing. The structure most buyers favor, ex-China rights with an option back into the mainland, hedges the political risk of owning Chinese clinical operations outright. It lets a Western company carry the molecule across the border while leaving the manufacturing footprint and the headline exposure behind, which goes a long way toward explaining why outright acquisitions of Chinese biotechs have stayed rare even as licensing has surged.
There is a caveat that the league tables tend to skip, and it carries real weight. The asset that set off the rush, Summit Therapeutics and Akeso’s PD-1/VEGF bispecific ivonescimab, has yet to produce a clean global validation. After it beat Keytruda on progression-free survival in a Chinese head-to-head trial, its first global Phase 3 readout, HARMONi, showed a 21% reduction in the risk of death that fell short of statistical significance, and Summit’s shares dropped sharply [12]. A separate China-only study, HARMONi-A, later posted a statistically significant survival benefit with a hazard ratio of 0.74 [13]. The Chinese data reads well; the global data reads ambiguously. That split is the central risk of the whole trade, distilled into a single molecule and a multiregional trial in which only 38% of patients came from the West [12]. Buyers are paying Western prices for efficacy that is still being established outside China.
What it means for each side
Western pharma can no longer treat China as an occasional source. The companies that staffed Shanghai and Hong Kong and built standing diligence pipelines two years ago will keep winning the better molecules from rivals who show up only when a deal already surfaces. Access has stopped being the differentiator now that everyone has it. What separates buyers is the ability to judge which China-only dataset will hold up in a global trial and which will not, and that is a clinical and statistical question far more than a relationship one.
For Chinese biotechs, the cheap era is ending on favorable terms. Hengrui raised about $1.29 billion in a Hong Kong IPO and still collected upfronts from both GSK and Merck in the same stretch [7]. Companies that had no leverage during the 2022 funding drought now face a genuine choice: license out for near-term cash, or hold an asset and develop it alone. The firms with real late-stage execution will increasingly choose to hold, which raises an uncomfortable possibility for buyers. The programs that keep reaching the West through licensing may skew toward the ones Chinese developers could not, or chose not to, finish themselves. Adverse selection is the quiet risk in a rising market.
For investors, the revaluation has already shown up in share prices and is now working its way through the upfronts. The next move depends on global readouts. If two or three flagship China-origin assets clear multiregional Phase 3 trials with clean overall-survival data, that 32% share of global licensing value starts to look like a floor. If more assets follow the ivonescimab pattern, winning at home and wobbling abroad, the upfront inflation could unwind faster than it built.
The arbitrage that opened this window is nearly gone. What appears set to replace it is a durable two-source model for global pharma innovation. China supplying a structural share of the molecules, the West supplying the capital, the commercial reach, and the regulatory access to its own market. The firms that read this correctly in 2024 are still buying at a discount that has largely disappeared. The rest are paying full price.
Author Bio
David H. Crean, Ph.D., MBA, Founder and Managing Partner of Cardiff Advisory LLC
David H. Crean, Ph.D., MBA is Founder and Managing Partner of Cardiff Advisory LLC, a M&A strategic advisory firm focused on M&A, partnering, and valuation services for life sciences and healthcare companies. He is a FINRA registered representative of BA Securities, LLC.
